drugset / Trial / NCT01842607

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

NCT01842607

Phase 3 Completed 651 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelTreatment

Summary

This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory asthma and a history of eosinophilic inflammation. Subjects who completed either MEA115588 or MEA115575 will be offered the opportunity to consent for this study.

Timeline

Start
2013-05-27
Primary completion
2015-03-13
Completion
2015-03-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Mepolizumab Monoclonal antibody 100 mg Subcutaneous

Indications